Middle East respiratory syndrome coronavirus infection CT
Middle East Respiratory Syndrome Coronavirus Infection Microchapters |
Differentiating Middle East Respiratory Syndrome Coronavirus Infection from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Middle East respiratory syndrome coronavirus infection CT On the Web |
American Roentgen Ray Society Images of Middle East respiratory syndrome coronavirus infection CT |
FDA on Middle East respiratory syndrome coronavirus infection CT |
CDC on Middle East respiratory syndrome coronavirus infection CT |
Middle East respiratory syndrome coronavirus infection CT in the news |
Blogs on Middle East respiratory syndrome coronavirus infection CT |
Directions to Hospitals Treating Middle East respiratory syndrome coronavirus infection |
Risk calculators and risk factors for Middle East respiratory syndrome coronavirus infection CT |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Middle East Respiratory Syndrome (MERS) is a viral respiratory illness. It is caused by an emerging coronavirus, specifically a betacoronavirus called MERS-CoV (Middle East Respiratory Syndrome Coronavirus), first discovered in 2012. Being a relatively novel virus, there is no virus-specific prevention or treatment options for MERS patients. Attending to the fact that a vaccine hasn't been developed yet, enhancing infection prevention and control measures is critical to prevent the possible spread of MERS-CoV in hospitals and communities. Persons with symptoms suspicious of MERS-CoV infection need medical evaluation. According to the CDC: a confirmed case of MERS-CoV infection is considered an individual who shows laboratory confirmation of infection by MERS-CoV. This last one is given by a positive PCR test of ≥2 specific genomic targets or, a single positive target followed by successful sequencing of a second. Aprobable case of MERS-CoV infection is an individual who has missing or inconclusive laboratory test results for the infection and that has been in close contact with another individual who is a "laboratory-confirmed case" of MERS-CoV infection.[1][2][3]Invalid parameter in <ref>
tag
CT
References
- ↑ Dyall J, Coleman CM, Hart BJ, Venkataraman T, Holbrook MR, Kindrachuk J; et al. (2014). "Repurposing of clinically developed drugs for treatment of Middle East Respiratory Coronavirus Infection". Antimicrob Agents Chemother. doi:10.1128/AAC.03036-14. PMID 24841273.
- ↑ "Clinical management of severe acute respiratory infections when novel coronavirus is suspected: What to do and what not to do" (PDF).
- ↑ "MERS Prevention and Treatment".